Articles

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

Institut de Cancérologie Gustave Roussy, Villejuif, France
Hospital Universitario de Salamanca, Salamanca, Spain
Institut de Cancérologie Gustave Roussy, Villejuif, France
Istituto Oncologico della Svizzera Italiana (IOSI) Ospedale San Giovanni, Bellinzona, Switzerland
Hospital Universitario de la Princesa, Madrid, Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hôpital Saint-Louis, Paris, France
Hospices Civils de Lyon, & Université Claude Bernard de Lyon, Lyon, France
Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, Milan, Italy
Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain
Istituto Oncologico della Svizzera Italiana (IOSI) Ospedale San Giovanni, Bellinzona, Switzerland
Vol. 98 No. 3 (2013): March, 2013 https://doi.org/10.3324/haematol.2012.069757